Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

Brian Slomovitz, Yunyun Jiang, Melinda S. Yates, Pamela T. Soliman, Taren Johnston, Maureen Nowakowski, Charles Levenback, Qian Zhang, Kari Ring, Mark F. Munsell, David M. Gershenson, Karen H. Lu, Robert L. Coleman

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Purpose: The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. Patients and Methods: Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response. Results: Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. Conclusion: Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.

Original languageEnglish (US)
Pages (from-to)930-936
Number of pages7
JournalJournal of Clinical Oncology
Volume33
Issue number8
DOIs
StatePublished - Mar 10 2015

Fingerprint

letrozole
Endometrial Neoplasms
Everolimus
Histology
Phosphotransferases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Slomovitz, B., Jiang, Y., Yates, M. S., Soliman, P. T., Johnston, T., Nowakowski, M., ... Coleman, R. L. (2015). Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. Journal of Clinical Oncology, 33(8), 930-936. https://doi.org/10.1200/JCO.2014.58.3401

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. / Slomovitz, Brian; Jiang, Yunyun; Yates, Melinda S.; Soliman, Pamela T.; Johnston, Taren; Nowakowski, Maureen; Levenback, Charles; Zhang, Qian; Ring, Kari; Munsell, Mark F.; Gershenson, David M.; Lu, Karen H.; Coleman, Robert L.

In: Journal of Clinical Oncology, Vol. 33, No. 8, 10.03.2015, p. 930-936.

Research output: Contribution to journalArticle

Slomovitz, B, Jiang, Y, Yates, MS, Soliman, PT, Johnston, T, Nowakowski, M, Levenback, C, Zhang, Q, Ring, K, Munsell, MF, Gershenson, DM, Lu, KH & Coleman, RL 2015, 'Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma', Journal of Clinical Oncology, vol. 33, no. 8, pp. 930-936. https://doi.org/10.1200/JCO.2014.58.3401
Slomovitz, Brian ; Jiang, Yunyun ; Yates, Melinda S. ; Soliman, Pamela T. ; Johnston, Taren ; Nowakowski, Maureen ; Levenback, Charles ; Zhang, Qian ; Ring, Kari ; Munsell, Mark F. ; Gershenson, David M. ; Lu, Karen H. ; Coleman, Robert L. / Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 8. pp. 930-936.
@article{c4a51c156b9a47e885387d98ce62e048,
title = "Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma",
abstract = "Purpose: The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. Patients and Methods: Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response. Results: Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40{\%} (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32{\%} (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. Conclusion: Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.",
author = "Brian Slomovitz and Yunyun Jiang and Yates, {Melinda S.} and Soliman, {Pamela T.} and Taren Johnston and Maureen Nowakowski and Charles Levenback and Qian Zhang and Kari Ring and Munsell, {Mark F.} and Gershenson, {David M.} and Lu, {Karen H.} and Coleman, {Robert L.}",
year = "2015",
month = "3",
day = "10",
doi = "10.1200/JCO.2014.58.3401",
language = "English (US)",
volume = "33",
pages = "930--936",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

AU - Slomovitz, Brian

AU - Jiang, Yunyun

AU - Yates, Melinda S.

AU - Soliman, Pamela T.

AU - Johnston, Taren

AU - Nowakowski, Maureen

AU - Levenback, Charles

AU - Zhang, Qian

AU - Ring, Kari

AU - Munsell, Mark F.

AU - Gershenson, David M.

AU - Lu, Karen H.

AU - Coleman, Robert L.

PY - 2015/3/10

Y1 - 2015/3/10

N2 - Purpose: The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. Patients and Methods: Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response. Results: Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. Conclusion: Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.

AB - Purpose: The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. Patients and Methods: Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response. Results: Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. Conclusion: Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.

UR - http://www.scopus.com/inward/record.url?scp=84924995823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924995823&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.58.3401

DO - 10.1200/JCO.2014.58.3401

M3 - Article

C2 - 25624430

AN - SCOPUS:84924995823

VL - 33

SP - 930

EP - 936

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -